Human cytochrome P450 2B6 genetic variability in Botswana: a case of haplotype diversity and convergent phenotypes

Leabaneng Tawe, Thato Motshoge, Pleasure Ramatlho, Naledi Mutukwa, Charles Waithaka Muthoga, Ghyslaine Bruna Djeunang Dongho, Axel Martinelli, Elias Peloewetse, Gianluca Russo, Isaac Kweku Quaye, Giacomo Maria Paganotti

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Identification of inter-individual variability for drug metabolism through cytochrome P450 2B6 (CYP2B6) enzyme is important for understanding the differences in clinical responses to malaria and HIV. This study evaluates the distribution of CYP2B6 alleles, haplotypes and inferred metabolic phenotypes among subjects with different ethnicity in Botswana. A total of 570 subjects were analyzed for CYP2B6 polymorphisms at position 516 G > T (rs3745274), 785 A > G (rs2279343) and 983 T > C (rs28399499). Samples were collected in three districts of Botswana where the population belongs to Bantu (Serowe/Palapye and Chobe) and San-related (Ghanzi) ethnicity. The three districts showed different haplotype composition according to the ethnic background but similar metabolic inferred phenotypes, with 59.12%, 34.56%, 2.10% and 4.21% of the subjects having, respectively, an extensive, intermediate, slow and rapid metabolic profile. The results hint at the possibility of a convergent adaptation of detoxifying metabolic phenotypes despite a different haplotype structure due to the different genetic background. The main implication is that, while there is substantial homogeneity of metabolic inferred phenotypes among the country, the response to drugs metabolized via CYP2B6 could be individually associated to an increased risk of treatment failure and toxicity. These are important facts since Botswana is facing malaria elimination and a very high HIV prevalence.
Original languageEnglish (US)
JournalScientific Reports
Issue number1
StatePublished - Mar 20 2018

Bibliographical note

KAUST Repository Item: Exported on 2020-10-01
Acknowledgements: We thank all the children in this study, and their parents and teachers, for their understanding and assistance. Furthermore, we thank all the staff for technical assistance in the blood collection and DNA extraction. We also thank Dr Gaseitsiwe S. from Botswana-Harvard Partnership (Gaborone, Botswana) for sequencing of the control genotypes included the two CC genotypes for 983 T > C polymorphism. This study was supported by Botswana Ministry of Health, the Penn Center for AIDS Research (CFAR), an NIH-funded program [grant # P30 AI 045008] and partly supported through the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [grant # DEL-15-006]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant # 107752/Z/15/Z] and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government.


Dive into the research topics of 'Human cytochrome P450 2B6 genetic variability in Botswana: a case of haplotype diversity and convergent phenotypes'. Together they form a unique fingerprint.

Cite this